Q2 Earnings Forecast for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Stock analysts at HC Wainwright issued their Q2 2027 earnings per share (EPS) estimates for CG Oncology in a note issued to investors on Friday, November 6th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.93) per share for the quarter. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.31) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2027 earnings at ($0.82) EPS.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.55 million.

Several other research firms have also issued reports on CGON. Truist Financial increased their price target on shares of CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Wall Street Zen raised shares of CG Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday. Wedbush boosted their price objective on shares of CG Oncology from $80.00 to $84.00 and gave the company an “outperform” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Thursday, October 15th. Finally, Guggenheim cut their target price on CG Oncology from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Monday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $88.11.

CG Oncology Trading Down 1.6%

Shares of NASDAQ:CGON opened at $74.74 on Monday. The firm has a 50 day moving average of $68.24 and a 200-day moving average of $66.18. The stock has a market capitalization of $6.62 billion, a PE ratio of -27.08 and a beta of 0.35. CG Oncology has a 12 month low of $35.80 and a 12 month high of $80.97.

Insider Buying and Selling

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the transaction, the director owned 1,000 shares of the company’s stock, valued at approximately $62,060. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 3,000 shares of company stock worth $209,580 over the last three months. 4.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CG Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in CG Oncology during the 2nd quarter worth approximately $444,509,000. Seven Fleet Capital Management LP boosted its position in CG Oncology by 24.5% in the second quarter. Seven Fleet Capital Management LP now owns 1,886,236 shares of the company’s stock valued at $134,017,000 after buying an additional 371,085 shares in the last quarter. Bank of America Corp DE grew its stake in shares of CG Oncology by 21.8% during the first quarter. Bank of America Corp DE now owns 1,449,364 shares of the company’s stock worth $98,093,000 after buying an additional 259,311 shares during the last quarter. EcoR1 Capital LLC grew its stake in shares of CG Oncology by 3.5% during the first quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock worth $74,583,000 after buying an additional 37,200 shares during the last quarter. Finally, Jefferies Financial Group Inc. grew its stake in shares of CG Oncology by 8.5% during the third quarter. Jefferies Financial Group Inc. now owns 835,342 shares of the company’s stock worth $59,217,000 after buying an additional 65,395 shares during the last quarter. 26.56% of the stock is owned by institutional investors.

About CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder.

Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

CG Oncology has no approved commercial products.